<DOC>
	<DOC>NCT00314054</DOC>
	<brief_summary>The purpose of this study is to assess the pharmacokinetics (PK) of HCV-796 in subjects with chronic hepatic impairment and in matched healthy adults.</brief_summary>
	<brief_title>Study Evaluating the Safety of HCV-796 in Subjects With Liver Disease and in Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Men and women of nonchildbearing potential. Hepatic impairment subjects: ChildPugh class A, B, or C according to the CP classification based on history, physical examination, and laboratory test results. Healthy volunteers: healthy as determined by the investigator. History of alcoholism within 1 year. Hepatic impairment subjects: evidence of unstable clinically significant disease other than impaired hepatic function. Healthy volunteers: positive serologic findings for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibodies.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Hepatic Impairment</keyword>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Hepacivirus</keyword>
</DOC>